

**Silence Therapeutics to Present at Upcoming Investor Conferences**

**London, [08] September, 2011** – Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”), a leading global RNA interference (RNAi) therapeutics company, today announced that Max Herrmann, chief financial officer and acting chief executive officer, and Thomas Christély, chief operating officer, will present corporate updates at two upcoming industry and financial conferences. Their presentations will include an update on corporate and clinical progress, including recently announced encouraging interim data from the Company’s ongoing Phase I trial of Atu027, Silence’s novel RNAi therapeutic for the treatment of advanced solid tumours. No new material information will be disclosed.

The conferences at which the Company will present are:

**Rodman & Renshaw 13<sup>th</sup> Annual Healthcare Conference**

11-13 September 2011

Waldorf Astoria Hotel, New York City

Max Herrmann’s presentation: 12:05 EST (17:05 BST, 18:05 CEST) on Tuesday, 13 September 2011, in the Starlight South room.

**Sachs Associates 11<sup>th</sup> Annual Biotech in Europe Investor Conference**

13-14 September 2011

Hilton Zurich Airport Hotel, Zurich

Thomas Christély’s presentation: 14:00 CEST (13:00 BST, 8:00 EST) on Tuesday, 13 September 2011

**Max Herrmann, chief financial officer and acting chief executive officer, commented:** *“We look forward to the opportunity to provide an update on Silence’s progress in 2011 and future plans at the upcoming investor conferences. Following the completion of our successful fundraising and the reorganisation and streamlining of the business, Silence is well positioned to strengthen its position as a leading RNAi therapeutics company.”*

A copy of these presentations will be available on Silence’s website at <http://www.silence-therapeutics.com/content/ir/events.htm> following the presentations.

--Ends--

**For further information, please contact:**

<p><b>Silence Therapeutics</b> Max Herrmann +44 20 7491 6520 <a href="mailto:m.herrmann@silence-therapeutics.com">m.herrmann@silence-therapeutics.com</a></p>	<p><b>Singer Capital Markets</b> Shaun Dobson/Claes Spång +44 20 32057500 <a href="mailto:shaun.dobson@singercm.com">shaun.dobson@singercm.com</a> <a href="mailto:claes.spang@singercm.com">claes.spang@singercm.com</a></p>
<p><b>Vida Communication (US)</b> Tim Brons (media)/Stephanie Diaz (investors) +1 (415) 675-7400 <a href="mailto:tbrons@vidacommunication.com">tbrons@vidacommunication.com</a> <a href="mailto:sdiaz@vidacommunication.com">sdiaz@vidacommunication.com</a></p>	<p><b>M:Communications (Europe)</b> Peter Laing / Emma Thompson +44 20 7920 2345 / +44 20 7920 2342 <a href="mailto:healthcare@mcomgroup.com">healthcare@mcomgroup.com</a></p>

## Notes for editors

### About Silence Therapeutics plc ([www.silence-therapeutics.com](http://www.silence-therapeutics.com))

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™ and DACC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the second half of 2011.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

### Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

###